Advanced Search

 

Study ID Status Title Patient Level Data
29060/402 Completed A double-blind, multicentre, parallel group study of paroxetine and amitriptyline in the treatment of patients with depression associated with breast cancer
29060/403 Completed Antidepressant efficacy and safety of paroxetine; a double blind amitriptyline controlled multicenter comparison study in depressive patients.
29060/406 Completed A Double-Blind, Long-Term Extension Study for Patients Previously Participating in Protocol 29060/131
29060/409 Completed A comparative, controlled double blind, double dummy study about the efficacy and safety of paroxetine vs imipramine in ambulatory patients with major depression
29060/418 Completed A single-dose 3-part crossover study to determine the comparative bioavailability of two oral liquid preparations of paroxetine (30 mg pfb) and a 30 mg tablet of paroxetine
29060/419 Completed A repeat-dose steady-state crossover evaluation of the bioequivalence of a 20 mg direct compression tablet of paroxetine with a 20 mg standard “Paxil” tablet
29060/421 Completed Paroxetine and Fluoxetine effects on mood and cognitive function in depressed nondemented elderly patients. Extensive searching has revealed that no clinical report is available for this study. The clinical trial results were reported via publications; see citation below.
29060/427 Completed A Multicentre, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Paroxetine (5mg OD Vs 10mg OD Vs 20mg OD) in Patients with Premenstrual Dysphoric Disorder (PMDD).
29060/433 Completed Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor
29060/436 Completed Safety Evaluation of Paroxetine in Elderly Depressed Patients
29060/437 Completed A Double-blind, Placebo-controlled Study to Investigate the Effect of Pindolol on the Onset of Anti-depressant Activity of Paroxetine in the Treatment of Depression.
29060/440 Completed A single dose 4-part crossover study to determine the comparative bioavailability of an oral liquid formulation of paroxetine (20 mg pfb) and a standard 20 mg pfb Paxil tablet administered immediately before and after breakfast
29060/442 Completed A multicentre, randomised, double-blind study to compare paroxetine versus placebo in the treatment of double depression.
29060/448 Completed A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression Study Listed on ClinicalStudyDataRequest.com
29060/449 Completed A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression Study Listed on ClinicalStudyDataRequest.com
29060/451 Completed An open 5 part crossover study to examine the bioavailability characteristics of two controlled-release and two delayed-release oral formulations of paroxetine (20 mg), in comparison with a standard 20 mg tablet, in healthy volunteers
29060/452 Completed A double-blind, placebo-controlled, parallel group study to investigate the incidence of nausea following 3 days treatment with modified release formulations of paroxetine compared with the standard immediate release paroxetine tablet at a dose level of 30 mg in healthy volunteers
29060/453 Completed A 38-Week, Two Phase, Multi-center Study to Investigate the Safety and Effectiveness of paroxetine (10-60mg/day in the Treatment of Children and Adolescent Outpatients with Obsessive Compulsive Disorder (OCD)
29060/454 Completed A Randomized, Double-Blind, Fixed Dose Comparison of 20, 40, and 60mg Daily of Paroxetine and Placebo in the Treatment of Generalized Social Phobia. Study Listed on ClinicalStudyDataRequest.com
29060/464 Completed Bioequivalence study of paroxetine hydrochloride formulations: bioequivalence study between two paroxetine hydrochloride 20 mg tablets of different formulas (new and old formula tablets) in healthy adult volunteers
29060/470 Completed An Extension Trial Comparing Paroxetine and Placebo in the Long Term Treatment of Generalized Social Phobia
29060/472 Completed A randomised, open, four-period crossover study to compare the pharmacokinetic profile of paroxetine after single doses of each enteric coated Geomatrix controlled-release tablet strength (12.5, 25, 37.5 and 50 mg)
29060/473 Completed A single dose, two-period crossover study to compare the bioavailability of paroxetine from the enteric-coated Geomatrix controlled-release paroxetine tablet (50 mg) when administered in the fasted state and after a standard FDA high-fat breakfast
29060/474 Completed A steady-state, two-period crossover study to compare the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled release paroxetine tablet (50 mg) with that of standard immediate release paroxetine (Paxil, 40 mg)
29060/475 Completed Pharmacokinetic study of paroxetine hydrochloridePharmacokinetics after single oral administration of paroxetine hydrochloride 20 mg to healthy elderly volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.